Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline by advancing its proprietary late stage photodynamic therapy (PDT) platform with broad utility for the treatment of unmet needs in cancer. PDT is a therapy that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of oxygen that induces local tumor cell death. Our PDT technology leverages a prior investment of over $200 million in clinical development and has the potential to address multiple cancer indications, particularly cutaneous cancers.
The Company's lead product candidate, REM-001 Therapy, consists of three parts, a laser light source, a light delivery device and the drug REM-001 (collectively, REM-001 Therapy). REM-001 Therapy has successfully completed four Phase 2/3 clinical studies demonstrating promising safety and efficacy in patients with cutaneous metastatic breast cancer (CMBC) who failed radiation therapy.
Use of our existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of our REM-001 product.